Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?
Yaser Pashaei
Journal of Clinical Neuroscience (2021) Vol. 88, pp. 163-172
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
Gilmar Reis, Eduardo Augusto dos Santos Moreira-Silva, Daniela Carla Medeiros Silva, et al.
The Lancet Global Health (2021) Vol. 10, Iss. 1, pp. e42-e51
Open Access | Times Cited: 374
Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment
Mario Gennaro Mazza, Mariagrazia Palladini, Sara Poletti, et al.
CNS Drugs (2022) Vol. 36, Iss. 7, pp. 681-702
Open Access | Times Cited: 159
Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants
Tomiko Oskotsky, Ivana Marić, Alice Tang, et al.
JAMA Network Open (2021) Vol. 4, Iss. 11, pp. e2133090-e2133090
Open Access | Times Cited: 127
Antidepressant psychopharmacology: is inflammation a future target?
Francesco Benedetti, Raffaella Zanardi, Mario Gennaro Mazza
International Clinical Psychopharmacology (2022) Vol. 37, Iss. 3, pp. 79-81
Closed Access | Times Cited: 39
Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19
Eliza Dąbrowska, Beata Galińska-Skok, Napoleon Waszkiewicz
Life (2021) Vol. 11, Iss. 10, pp. 1056-1056
Open Access | Times Cited: 42
Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort
Catherine L. Clelland, Krista Ramiah, Louisa J. Steinberg, et al.
BJPsych Open (2021) Vol. 8, Iss. 1
Open Access | Times Cited: 42
A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies
Changxing Li, Sobia Noreen, Lixue Zhang, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112550-112550
Open Access | Times Cited: 41
Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19
Mohamed Mahdi, Levente Hermán, János Réthelyi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3812-3812
Open Access | Times Cited: 33
Blocking TNF signaling may save lives in COVID-19 infection
Vitaly Ablamunits, Christopher Lepsy
Molecular Biology Reports (2022) Vol. 49, Iss. 3, pp. 2303-2309
Open Access | Times Cited: 31
The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis
Hosein Nakhaee, Moein Zangiabadian, R. Bayati, et al.
PLoS ONE (2022) Vol. 17, Iss. 10, pp. e0267423-e0267423
Open Access | Times Cited: 26
Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19
Nicolas Hoertel, Marina Sánchez‐Rico, Johannes Kornhuber, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 19, pp. 5882-5882
Open Access | Times Cited: 24
Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study
Irene Visos‐Varela, Maruxa Zapata‐Cachafeiro, María Piñeiro‐Lamas, et al.
European Neuropsychopharmacology (2023) Vol. 71, pp. 96-108
Open Access | Times Cited: 13
Exploring the causal effects of depression and antidepressants on COVID-19
Li Fu, Ancha Baranova, Hongbao Cao, et al.
Journal of Affective Disorders (2024) Vol. 359, pp. 350-355
Closed Access | Times Cited: 4
The Neurobiology of Comorbidities
Mojtaba Oraki Kohshour, Alba Navarro-Flores, Monika Budde, et al.
(2025), pp. 89-125
Closed Access
Neuropsychiatric Manifestations of Long COVID-19: A Narrative Review of Clinical Aspects and Therapeutic Approaches
Olga Adriana Căliman-Sturdza, Roxana Gheorghiţă, Andrei Lobiuc
Life (2025) Vol. 15, Iss. 3, pp. 439-439
Open Access
PANDAS/PANS in the COVID-19 Age: Autoimmunity and Epstein–Barr Virus Reactivation as Trigger Agents?
Stefano Pallanti, Michele Di Ponzio
Children (2023) Vol. 10, Iss. 4, pp. 648-648
Open Access | Times Cited: 10
DTSEA: A network-based drug target set enrichment analysis method for drug repurposing against COVID-19
Yinchun Su, Jiashuo Wu, Xiangmei Li, et al.
Computers in Biology and Medicine (2023) Vol. 159, pp. 106969-106969
Open Access | Times Cited: 10
Deleterious effects of nervous system in the offspring following maternal SARS-CoV-2 infection during the COVID-19 pandemic
Ruting Wang, Zifeng Wu, Chaoli Huang, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 15
The relationship between the serotonergic system and COVID-19 disease: A review
Tahereh Eteraf-Oskouei, Moslem Najafi
Heliyon (2022) Vol. 8, Iss. 5, pp. e09544-e09544
Open Access | Times Cited: 14
Ongoing Use of SSRIs Does Not Alter Outcome in Hospitalized COVID-19 Patients: A Retrospective Analysis
Steven H. Rauchman, Sherri Mendelson, Courtney Rauchman, et al.
Journal of Clinical Medicine (2021) Vol. 11, Iss. 1, pp. 70-70
Open Access | Times Cited: 18
Drug Repurposing: Escitalopram attenuates acute lung injury by inhibiting the SIK2/ HDAC4/ NF-κB signaling cascade
Tiantian Wang, Ruihe Zheng, Song Yung Sun
Biochemical and Biophysical Research Communications (2022) Vol. 599, pp. 1-8
Closed Access | Times Cited: 11
Potential of Azadirachta indica as a Capping Agent for Antiviral Nanoparticles against SARS-CoV-2
Frank Eric Tatsing Foka, Nanabi Manamela, Maluta Steven Mufamadi, et al.
BioMed Research International (2022) Vol. 2022, pp. 1-12
Open Access | Times Cited: 9
The effectiveness and tolerability of agomelatine in the treatment of depression after COVID-19 infection in Russian daily clinical practice (TELESPHOR study)
В Э Медведев, А Н Боголепова, Denis P. Morozov, et al.
Authorea (Authorea) (2024)
Open Access | Times Cited: 1
COVID-19 Prognosis in Association with Antidepressant Use
Kyung Hyun Min, Tae Hyeok Kim, Soo Jin Oh, et al.
Pharmacopsychiatry (2022) Vol. 55, Iss. 04, pp. 220-227
Open Access | Times Cited: 6
Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection
Pascal Le Corre, Gwenolé Loas
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top